Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients

Journal of Clinical Pharmacology

Volumn 56, Issue 5, 2016, Pages 567-575

  Godoy, Ana Leonor Pardo Campos ^a   Rocha, Adriana ^a   Da Silva Souza, Cacilda ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

enantiomers; metabolism; pharmacokinetics; psoriasis; venlafaxine

Indexed keywords

CYTOCHROME P450 2D6; DESVENLAFAXINE; DRUG METABOLITE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; N DESMETHYLVENLAFAXINE; N,O DIDESMETHYLVENLAFAXINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYTOKINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; HUMAN; MALE; PHENOTYPE; PROTEIN BLOOD LEVEL; PSORIASIS; RACEMIC MIXTURE; SINGLE DRUG DOSE; BLOOD; CHEMISTRY; CONTROLLED CLINICAL TRIAL; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; STEREOISOMERISM; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; CYTOKINES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; STEREOISOMERISM; VENLAFAXINE HYDROCHLORIDE; YOUNG ADULT;

EID: 84948165984     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.630     Document Type: Article

References (29)

1. Menter A, Gottlieb A, Feldman SR, et al., Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58 (5): 826-850.
2. Martínez-García E, Arias-Santiago S, Valenzuela-Salas I, Garrido-Colmenero C, García-Mellado V, Buendía-Eisman A., Quality of life in persons living with psoriasis patients. J Am Acad Dermatol. 2014; 71 (2): 302-307.
3. Daudén E, Castañeda S, Suárez C, et al., Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013; 27 (11): 1387-1404.
4. Ni C, Chiu MW., Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014; 7: 119-132.
5. Machavaram KK, Almond LM, Rostami-Hodjegan A, et al., A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther. 2013; 94 (2): 260-268.
6. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG., Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 2011; 39 (8): 1415-1422.
7. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey J-L, Bertschy G., Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol. 2004; 59 (12): 883-891.
8. Dutta L, Ahmad SI, Mukherjee SK, Mishra S, Khuroo A, Monif T., Liquid chromatography tandem mass spectrometry method for the simultaneous stereoselective determination of venlafaxine and its major metabolite, O-desmethylvenlafaxine, in human plasma. Biomed Chromatogr. 2013; 27 (5): 622-635.
9. Sansone RA, Sansone LA., Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014; 11 (3-4): 37-42.
10. Gex-Fabry M, Rudaz S, Balant-Gorgia AE, et al., Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. Eur J Clin Pharmacol. 2002; 58 (5): 323-331.
11. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST., Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 1992; 32 (8): 716-724.
12. Sánchez C, Hyttel J., Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol. 1999; 19 (4): 467-489.
13. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB., Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol. 1986; 35 (24): 4493-4497.
14. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM., Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991; 23 (2): 191-199.
15. Kandasamy M, Srinivas P, Subramaniam K, et al., Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes-focus on venlafaxine and O-desmethylvenlafaxine. Eur J Clin Pharmacol. 2010; 66 (9): 879-887.
16. Eap CB, Lessard E, Baumann P, et al., Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics. 2003; 13 (1): 39-47.
17. Olver JS, Burrows GD, Norman TR., The treatment of depression with different formulations of venlafaxine: a comparative analysis. Hum Psychopharmacol. 2004; 19 (1): 9-16.
18. Feldman SR, Krueger GG., Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2): ii65-ii68; discussion ii69-ii73.
19. Bouguéon K, Misery L., Depression and psoriasis. Ann Dermatol Venereol. 2008; 135 (Suppl): S254-S258.
20. Golpour M, Hosseini SH, Khademloo M, et al., Depression and Anxiety Disorders among Patients with Psoriasis: A Hospital-Based Case-Control Study. Dermatol Res Pract. 2012; 2012: ID381905.
21. Van Voorhees AS, Fried R., Depression and quality of life in psoriasis. Postgrad Med. 2009; 121 (4): 154-161.
22. Kandhwal K, Dey S, Nazarudheen S, et al., Establishing bioequivalence of racemic venlafaxine formulations using stereoselective assay method: Is it necessary ? Chirality. 2011; 23 (10): 948-954.
23. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM., Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996; 41 (2): 149-156.
24. Fogelman SM, Schmider J, Venkatakrishnan K, et al., O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999; 20 (5): 480-490.
25. Kingbäck M, Karlsson L, Zackrisson A-L, et al., Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. Forensic Sci Int. 2012; 214 (1-3): 124-134.
26. Wijnen PAHM, Limantoro I, Drent M, Bekers O, Kuijpers PMJC, Koek GH., Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity. Ann Clin Biochem. 2009; 46 (Pt 6): 527-530.
27. Morgan ET, Goralski KB, Piquette-Miller M, et al., Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008; 36 (2): 205-216.
28. Arican O, Aral M, Sasmaz S, Ciragil P., Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; 2005 (5): 273-279.
29. Lanchote VL, Almeida R, Barral A, et al., Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients. Br J Clin Pharmacol. 2015; DOI: 10.1111/bcp.12677